Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CD255 Antikörper

Der Maus Monoklonal Anti--Antikörper wurde für FACS, IHC und Func validiert. Er ist geeignet, in Proben von Human zu detektieren. Es sind 6+ Publikationen verfügbar.
Produktnummer ABIN2749023

Kurzübersicht für CD255 Antikörper (ABIN2749023)

Target

CD255

Reaktivität

  • 7
  • 1
Human

Wirt

  • 7
  • 1
Maus

Klonalität

  • 8
Monoklonal

Konjugat

  • 4
  • 4
Unkonjugiert

Applikation

  • 8
  • 4
  • 2
  • 1
Flow Cytometry (FACS), Immunohistochemistry (IHC), Functional Studies (Func)

Klon

CARL-1
  • Verwendungszweck

    Anti-Hu CD255 Purified Low Endotoxin

    Spezifität

    The mouse monoclonal antibody CARL-1 recognizes an extracellular epitope of CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to induce apoptosis weakly in many cell types.

    Kreuzreaktivität (Details)

    Human

    Aufreinigung

    Purified by protein-A affinity chromatography.

    Reinheit

    > 95 % (by SDS-PAGE)

    Endotoxin-Niveau

    Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.

    Immunogen

    human CD255-transfected 2PK-3 cells

    Isotyp

    IgG3 kappa
  • Applikationshinweise

    Functional application: Neutralization.
    Flow cytometry: Recommended dilution: 1-4 μg/mL

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Konzentration

    1 mg/mL

    Buffer

    Tris buffered saline (TBS), pH 8.0

    Lagerung

    4 °C

    Informationen zur Lagerung

    Store at 2-8°C. Do not freeze.
  • Yoriki, Akashi, Sho, Nomi, Yamato, Hotta, Takayama, Matsumoto, Wakatsuki, Migita, Yagita, Nakajima: "Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).

    Brown, Ghosh, Winkles: "Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway." in: The Journal of biological chemistry, Vol. 285, Issue 23, pp. 17432-41, (2010) (PubMed).

    Hosokawa, Hosokawa, Ozaki, Nakae, Matsuo: "Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts." in: Clinical and experimental immunology, Vol. 146, Issue 3, pp. 540-9, (2006) (PubMed).

    Saitoh, Nakayama, Nakano, Yagita, Yamamoto, Yamaoka: "TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation." in: The Journal of biological chemistry, Vol. 278, Issue 38, pp. 36005-12, (2003) (PubMed).

    Nakayama, Ishidoh, Kojima, Harada, Kominami, Okumura, Yagita: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 1, pp. 341-8, (2002) (PubMed).

    Nakayama, Kayagaki, Yamaguchi, Okumura, Yagita: "Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity." in: The Journal of experimental medicine, Vol. 192, Issue 9, pp. 1373-80, (2000) (PubMed).

  • Target

    CD255

    Hintergrund

    TNF superfamily member 12,CD255 / TWEAK (TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 / TWEAK R. On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumours. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.,TNFSF12, APO3L, DR3LG, TWEAK, TNLG4A

    Gen-ID

    8742

    UniProt

    O43508
Sie sind hier:
Chat with us!